Payment overview · 2025
General Payments
$2,261.40
117 reported records · 18 companies
Healthcare provider profile · identity verified
John A. Spence, M. D.
Allopathic & Osteopathic Physicians|Family Medicine · MARIANNA, FL · NPI 1497794796
Verified facts
What the public records show
CMS Open Payments records show John A. Spence, M. D. received $2,261.40 in general payments during 2025 across 117 reported records.
Novo Nordisk Inc accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Otezla, Ozempic, Trelegy Ellipta, Verquvo, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $472.33 | 20.9% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $340.46 | 15.1% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $312.13 | 13.8% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $188.68 | 8.3% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $178.78 | 7.9% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $153.97 | 6.8% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $143.86 | 6.4% | 8 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.58 | 3.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.87 | 3.3% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $59.51 | 2.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.42 | 2.1% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $42.89 | 1.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.03 | 1.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.83 | 1.8% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $36.12 | 1.6% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.37 | 0.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.12 | 0.8% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.45 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,261.40 | 117 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $332.46 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $207.38 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $204.93 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $178.78 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $172.49 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $172.49 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $166.12 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $143.86 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $139.87 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $112.42 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $99.55 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $83.20 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $79.58 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $69.46 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.73 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $60.61 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $59.51 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $51.88 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.42 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $40.03 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.83 | 2 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.49 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 221 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 166 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
221 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
166 | 35 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 513 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 133 |
| Gabapentin | Gabapentin | 436 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 419 | 97 |
| Omeprazole | Omeprazole | 362 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 341 | 81 |
| Furosemide | Furosemide | 316 | 75 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 316 | 56 |
| Potassium Chloride | Potassium Chloride | 303 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 77 |
| Alprazolam | Alprazolam | 282 | 53 |
| Tramadol Hcl | Tramadol Hcl | 272 | 60 |
| Losartan Potassium | Losartan Potassium | 266 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 57 |
| Metformin Hcl | Metformin Hcl | 258 | 65 |
| Valsartan | Valsartan | 238 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 55 |
| Jardiance | Empagliflozin | 221 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 57 |
| Lisinopril | Lisinopril | 212 | 66 |
| Trazodone Hcl | Trazodone Hcl | 207 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 204 | 58 |
| Allopurinol | Allopurinol | 184 | 37 |
| Mounjaro | Tirzepatide | 184 | 25 |
| Meloxicam | Meloxicam | 173 | 48 |
| Simvastatin | Simvastatin | 171 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 166 | 35 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 150 | 47 |
| Carvedilol | Carvedilol | 141 | 34 |
| Glipizide | Glipizide | 138 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 136 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 36 |
| Pregabalin | Pregabalin | 116 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 36 |
| Donepezil Hcl | Donepezil Hcl | 111 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 21 |
| Sertraline Hcl | Sertraline Hcl | 110 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 22 |
| Clonazepam | Clonazepam | 102 | 22 |
| Famotidine | Famotidine | 100 | 22 |
| Montelukast Sodium | Montelukast Sodium | 94 | 23 |
| Bumetanide | Bumetanide | 88 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 23 |
| Prednisone | Prednisone | 84 | 57 |
| Morphine Sulfate Er | Morphine Sulfate | 83 | 11 |
| Celecoxib | Celecoxib | 78 | 16 |
| Mirtazapine | Mirtazapine | 78 | 26 |
| Temazepam | Temazepam | 78 | 14 |
| Eliquis | Apixaban | 77 | 20 |
| Cefdinir | Cefdinir | 76 | 67 |
| Estradiol | Estradiol | 76 | 20 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 74 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 73 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 73 | 20 |
| Xarelto | Rivaroxaban | 67 | 11 |
| Glipizide Er | Glipizide | 65 | 14 |
| Methocarbamol | Methocarbamol | 64 | 21 |
| Propranolol Hcl | Propranolol Hcl | 63 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 18 |
| Promethazine Hcl | Promethazine Hcl | 62 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 20 |
| Glimepiride | Glimepiride | 59 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 11 |
| Metformin Hcl Er | Metformin Hcl | 51 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 51 | 15 |
| Buspirone Hcl | Buspirone Hcl | 50 | 15 |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 47 | 12 |
| Spironolactone | Spironolactone | 47 | 18 |
| Linzess | Linaclotide | 46 | 14 |
| Levetiracetam | Levetiracetam | 45 | 12 |
| Naproxen | Naproxen | 45 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 14 |
| Warfarin Sodium | Warfarin Sodium | 44 | 11 |
| Azelastine Hcl | Azelastine Hcl | 43 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 43 | suppressed |
| Fentanyl | Fentanyl | 43 | suppressed |
| Topiramate | Topiramate | 42 | 13 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Levofloxacin | Levofloxacin | 41 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 32 |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 29 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | 12 |
| Alendronate Sodium | Alendronate Sodium | 37 | 15 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 36 | suppressed |
| Nystatin | Nystatin | 36 | 15 |
| Ozempic | Semaglutide | 36 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | 12 |
| Vraylar | Cariprazine Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 13 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 21 |
| Metolazone | Metolazone | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 15 |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 13 |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Atenolol | Atenolol | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 17 |
| Valacyclovir | Valacyclovir Hcl | 21 | 11 |
| Buprenorphine | Buprenorphine | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Cefprozil | Cefprozil | 20 | 19 |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 20 | 17 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Verquvo | Vericiguat | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Veozah | Fezolinetant | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Linezolid | Linezolid | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Mupirocin | Mupirocin Calcium | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,261.40 · 117 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Ambulatory Monitoring & Diagnostics Undivided, BREZTRI, CAPLYTA, CAPVAXIVE, EVENITY, FANAPT, FARXIGA, FUROSCIX, JARDIANCE, JASCAYD, JOURNAVX, Kerendia, LEQVIO, NURTEC ODT, OFEV, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, QULIPTA, Qelbree, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error